It is widely accepted that the use of immunotherapy agents has been one of the major advances in oncology over recent years.

But what further changes can we expect as the area develops in the next few years, and what does that mean for pharma? To look further into these important questions, Beyond Blue have conducted self-funded research with 5 global KOLs¹ to understand these future perspectives and the opportunities for new checkpoint inhibitors and costimulatory agonists. Their views, and their implications, are discussed here.